T cells are at the center of cancer immunology because of their ability to recognize mutations
in tumor cells and directly mediate cancer cell killing. Immunotherapies to rejuvenate …

T cells are central players in cancer immunotherapy. Despite much concentrated effort on
the study of tumor-infiltrating lymphocytes (TIL), such as T cells, a series of fundamental …

Advances in molecular biology, microfluidics and bioinformatics have empowered the study
of thousands or even millions of individual cells from malignant tumours at the single-cell …

Visualization of the cellular heterogeneity and spatial architecture of the tumor
microenvironment (TME) is becoming increasingly important to understand mechanisms of …

Clinically relevant immunological biomarkers that discriminate between diverse
hypofunctional states of tumor-associated CD8+ T cells remain disputed. Using multiomics …

Most current tumor immunotherapy strategies leverage cytotoxic CD8+ T cells. Despite
evidence for clinical potential of CD4+ tumor-infiltrating lymphocytes (TILs), their functional …

INTRODUCTION Cancer immunotherapies that target tumor-specific T cells have benefited
many cancer patients, but the clinical efficacy varies greatly among different cancer types …

Single-cell sequencing opens a new era for the investigation of tumor immune
microenvironments (TIME). However, at single-cell resolution, a pan-cancer analysis that …

Human T cells coordinate adaptive immunity in diverse anatomic compartments through
production of cytokines and effector molecules, but it is unclear how tissue site influences T …

Immunocyte infiltration and cytotoxicity play critical roles in both inflammation and
immunotherapy. However, current cancer immunotherapy screening methods overlook the …